

# 1<sup>ST</sup> CURRENT CHALLENGES, CONTROVERSIES AND CONSENSUS IN ONCOLOGY

22<sup>ND</sup> & 23<sup>RD</sup> FEB, 2025 | WelcomHotel By ITC, Guntur



*Chief Guest*

**Prof (Dr.) Sagar TG**

Chairman & Prof, Dept of Medical Oncology,  
Cancer Institute (WIA) Adyar,  
Chennai



*Guest of Honor & Keynote Speaker*

**Prof (Dr.) Purvish Parikh**

Medical Oncology & Hematology,  
Prof & Head of Clinical Hematology, MGMC&H,  
Jaipur



*Chief Patron*

**Dr. D.S. Raju Naidu**

Director and Consultant Radiation Oncologist,  
Arka Hospital & Research Institute, Guntur



*Chief Patron*

**Dr. M. Ramakrishna Reddy**

Director and Head of Neurosciences,  
Uday Hospital, Guntur



*Organizing Chairperson*

**Dr. Hemanth Makineni**

Director and Consultant Surgical Oncologist,  
Arka Hospital & Research Institute, Guntur



*Program Director*

**Dr. K Pavan Raghava Reddy**

Director & Consultant  
Medical, Pediatric and Hemato-Oncologist,  
Arka Hospital & Research Institute, Guntur



*Program Director*

**Dr. S Krupa Shankar**

Director & Consultant,  
Medical Oncologist,  
NSR CanKure Center, Coimbatore



*Scientific Chairperson*

**Dr. Vijay G**

Consultant Hemato Oncologist &  
Medical Oncologist, VS Hospitals,  
Chennai

ANDHRA PRADESH MEDICAL COUNCIL HAS GRANTED 3 (THREE) CREDIT HOURS FOR THE CONFERENCE



**CLICK HERE TO REGISTER**

IN CASE YOU ARE UNABLE TO ACCESS THE LINK ON YOUR PHONE,  
PLEASE DOWNLOAD THE WPS OFFICE APP FROM THE PLAY STORE/APP STORE



+91 88982 32348



c4nationalconference@gmail.com



www.1stc4nationalconference.com

# 1<sup>ST</sup> CURRENT CHALLENGES, CONTROVERSIES AND CONSENSUS IN ONCOLOGY

22<sup>ND</sup> & 23<sup>RD</sup> FEB, 2025 | WelcomHotel By ITC, Guntur

## ORGANIZING COMMITTEE

**CHAIRPERSON - Dr. Hemanth Makineni**

Dr. Ashwin Philips

Dr. G Ranga Raman

Dr. Gundrathi Vamsivihari

Dr. Saikrishna Kolluru

Dr. Himani

Dr. Satya Srinivas Appala

Dr. Ramavath Dev

Dr. Vasu Babu Goli

Dr. Y Ramakrishna Reddy

Dr. Vishwajeeth Pai

## SCIENTIFIC COMMITTEE

**CHAIRPERSON - Dr. Vijay G**

Dr. Kiran Kumar DVS

Dr. Abhishek Raghava

Dr. Bhaskar Bhuvan

Dr. Sivaramakrishna TV

Dr. Sharada Mailankody

Dr. Deepak Koppaka

**Day 1 | 22nd February, 2025 | Saturday**

9:00 am to 9:05 am	<b>Welcome Address</b>	
9:05 am to 9:55 am	<b>Academic Session 1 - Head and Neck Oncology</b> Chairpersons: Dr. Senthil Rajappa & Dr. Gorijavolu Durgaprasad	
9:05 - 9:10	Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008)	Dr. Saikrishna Kolluru
9:10 - 9:15	Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma	Dr. Ashwin Philips
9:15 - 9:20	Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651	Dr. Satya Srinivas Appala
9:20 - 9:25	Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients with Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation	Dr. Lakshmi Priyadarshini K
9:30 - 9:55	Panel Discussion Moderator: Dr. Vijay G Panelists: Dr. Mahathi T, Dr. Sravanthi Byrapaneni, Dr. Saikrishna Kolluru, Dr. Ashwin Philips, Dr. Satya Srinivas Appala & Dr. Lakshmi Priyadarshini K	
9:55 am to 10:35 am	<b>Sponsored Session 1 (Bristol Myers Squibb)</b> Panel Discussion - Improving Survival and Quality of Life in frontline advanced RCC with CTLA-4 & PD-1 inhibition Moderator - Dr. Senthil Rajappa Panelists - Dr. Sreekant Boga, Dr. Vasu Babu Goli, Dr. Appala Satya Srinivas & Dr. Ram Prahlad	
10:35 am to 11:20 am	<b>Academic Session 2 - Genito-Urinary Oncology</b> Chairpersons - Dr. N Subba Rao & Dr. Chebrolu Visweswararao	
10:35 - 10:40	Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma (COSMIC313)	Dr. Kharthik Natramilarasu
10:40 - 10:45	Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2)	Dr. Sai Madhuri Boppana
10:45 - 10:50	Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR trial)	Dr. Hemanth Kumar
10:50 - 10:55	Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer (NIAGARA trial)	Dr. Shoufeej P M
10:55 - 11:20	Panel Discussion Moderator: Dr. Senthil Rajappa Panelists: Dr. Sindhu Kilaru, Dr. Sreekanth Boga, Dr. Kharthik Natramilarasu, Dr. Sai Madhuri Boppana, Dr. Hemanth Kumar & Dr. Shoufeej P M	
11:20 am to 11:40 am	<b>Tea Break</b>	
11:50 am to 12:05 pm	<b>Sponsored Session 2 (Bayer)</b> ARASENS - Clinical Evidence: Darolutamide and Survival in Metastatic Hormone Sensitive Prostate Cancer Speaker - Dr. Senthil Rajappa	
12:05 pm to 12:25 pm	<b>Inauguration</b>	

12:25 pm to 12:55 pm	<b>Artificial Intelligence - Practical Implications TODAY for doctors and medical students</b> <b>Keynote Speaker - Dr. Purvish Parikh</b>	
1:00 pm to 2:00 pm	<b>Lunch</b>	
2:00 pm to 2:25 pm	<b>Day 1 Plenary Session</b> <b>Current Challenges, Controversies and Consensus in Oligometastatic Breast Cancer: C4 in OMBC!</b> <b>Speaker - Dr. S Krupashankar</b>	
2:30 pm to 3:20 pm	<b>Academic Session 3 - Gynae-Oncology</b> Chairpersons: Dr. Sivaramakrishna TV & Dr. Srinivasa Rao Nuthalapati	
2:30 - 2:35	Mirvetuximab Soravtansine in FR $\alpha$ -Positive, Platinum-Resistant Ovarian Cancer (MIRASOL)	Dr. Vijay G
2:35 - 2:40	Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab with or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer (DUO-E)	Dr. G Ranga Raman
2:40 - 2:45	Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc)	Dr. SV Saju
2:45 - 2:50	Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer (SHAPE trial)	Dr. Kalyan Chakradhar Polavarapu
2:55 - 3:20	Panel Discussion Moderator: Dr. Bhavesh Poladia Panelists: Dr. Murali Nalabotu, Dr. Y Ramakrishna Reddy, Dr. Vijay G, Dr. G Ranga Raman, Dr. Kalyan Chakradhar Polavarapu & Dr. SV Saju	
3:20 pm to 3:35 pm	<b>Sponsored Session 3 (Zydus)</b> Present and Future Landscape of HER2+ Breast Cancer Management Speaker - Dr. Ramavath Dev	
3:35 pm to 3:50 pm	<b>Sponsored Session 4 (Eris)</b> Long Term Survival Outcomes with Nimotuzumab in combination with concurrent chemo radiation in locally advanced Head and Neck Cancer Speaker - Dr. Mahathi T	
3:55 pm to 4:10 pm	<b>Tea Break</b>	
4:10 pm to 5:00 pm	<b>Academic Session 4 - Thoracic-Oncology</b> Chairpersons: Dr. Purvish Parikh & Dr. C Haritha	
4:10 - 4:15	Phase 3 study of ivonescimab (AK112) vs pembrolizumab as first-line treatment for PD-L1–positive advanced NSCLC (HARMONi-2)	Dr. Deepak Koppaka
4:15 - 4:20	Efficacy and safety of datopotamab deruxtecan in patients with previously treated EGFR mutated advanced non small cell lung cancer (NSCLC): pooled analysis of TROPION Lung01 and TROPION Lung05	Dr. Ramavath Dev
4:20 - 4:25	Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC (PACIFIC-2)	Dr. Minu Chandra
4:25 - 4:30	Perioperative Nivolumab in Resectable Lung Cancer (CheckMate 77T)	Dr. Sharada Mailankody
4:35 - 5:00	Panel Discussion Moderator: Dr. Rejiv Rajendranath Panelists: Dr. Haneesha Polavarapu, Dr. Ramu Kandula, Dr. Deepak Koppaka, Dr. Ramavath Dev, Dr. Minu Chandra & Dr. Sharada Mailankody	

5:05 pm to 5:20 pm	<p align="center"><b>Sponsored Session 5 (J&amp;J)</b> Transforming NSCLC Treatment: Amivantamab role in Targeting Exon 20 Insertions Speaker - Dr. Deepak Koppaka</p>
5:20 pm to 5:40 pm	<p align="center"><b>Sponsored Session 6 (AstraZeneca)</b> Optimizing the management of advanced EGFRm NSCLC with chemotherapy combinations Speaker - Dr. S Krupashankar</p>
5:40 pm to 6:00 pm	<p align="center"><b>Sponsored Session 7 (AstraZeneca)</b> Transforming patient outcomes with Newer innovative therapies in 1L Advanced mHCC (STRIDE) Speaker - Dr. Bhaskar Bhuvan</p>
6:00 pm to 6:20 pm	<p align="center"><b>Sponsored Session 8 (MSD)</b> Novel treatment options in lung cancer with focus on Pembrolizumab Speaker - Dr. Ramavath Dev</p>
6:20 pm to 6:40 pm	<p align="center"><b>Sponsored Session 9 (MSD)</b> Role of IO and its sequencing strategy in the management of HNSCC Speaker - Dr. Rajesh Kota</p>

**Day 2 | 23rd February, 2025 | Sunday**

9:00 am to 9:45 am	<p align="center"><b>Academic Session 5 - GI/HPB-Oncology</b> Chairpersons: Prof. T S Ganesan &amp; Dr. Sreekanth Kotagiri</p>	
9:00 - 9:05	Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585)	Dr. Kiran Kumar DVS
9:05 - 9:10	Transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization (EMERALD1)	Dr. Abhishek Raghava
9:10 - 9:15	Cell-free DNA Blood-Based Test for Colorectal Cancer Screening (ECLIPSE)	Dr. Manuprasad A
9:15 - 9:20	Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1)	Dr. Sainath Bhethanabhotla
9:20 - 9:45	<p>Panel Discussion Moderator: Dr. Krishna Prasad Panelists: Dr. Minu Chandra, Dr. Bharati Devi Gorantla, Dr. Narendran Krishnamoorthi, Dr. Kiran Kumar DVS, Dr. Abhishek Raghava, Dr. Manuprasad A &amp; Dr. Sainath Bhethanabhotla</p>	
9:45 am to 10:00 am	<p align="center"><b>Sponsored Session 10 (Ampath Labs)</b> From sample to slide: Getting the most out of the IHC with effective laboratory management system Speaker - Dr. Megha Yadav Deshabhotla</p>	
10:00 am to 10:50 am	<p align="center"><b>Academic Session 6 - Hematology</b> Chairpersons: Prof. TG Sagar &amp; Dr. Rajesh Mallik Gottipati</p>	
10:00 - 10:05	Asciminib add-on to Imatinib (ASC4MORE trial)	Dr. Rakesh Reddy Boya
10:05 - 10:10	Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)	Dr. Jayachandran P K
10:10 - 10:15	Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia (AMPLIFY trial)	Dr. Vasu Babu Goli

10:15 - 10:20	Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma (MATRix/IELSG43)	Dr. AMVR Narendra
10:20 - 10:50	Panel Discussion Moderator: Dr. Sachin Jadhav Panelists: Dr. Jeyasankar S, Dr. Narendran Krishnamoorthi, Dr. Rakesh Reddy Boya, Dr. Jayachandran P K, Dr. Vasu Babu Goli & Dr. AMVR Narendra	
10:50 am to 11:10 am	<b>Sponsored Session 11 (Bristol Myers Squibb)</b> Breaking frontiers in 1L mNSCLC Leveraging Anti PD-1 & Anti CTLA-4 for high unmet need patients Speaker - Dr. Rakesh Reddy Boya	
11:10 am to 11:20 am	<b>Tea Break</b>	
11:20 am to 11:45 am	<b>Day 2 Plenary Session</b> <b>Topic: Indications and Interpretations of NGS in oncology – A clinician’s perspective</b> <b>Speaker - Dr. TS Ganesan</b>	
11:45 am to 12:30 pm	<b>Academic Session 7 - Breast-Oncology</b> Chairpersons: Dr. S Krupa Shankar & Dr. AY Rao	
11:45 - 11:50	Adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer (NATALEE Update)	Dr. Rajesh Kota
11:50 - 11:55	Sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPICS02)	Dr. Vishwajeeth Pai
11:55 - 12:00	Nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer (CheckMate 7FL)	Dr. Nagender Sharma
12:00 - 12:05	Benefit of Adjuvant Regional Nodal Irradiation in Patients with Early Breast Cancer Converting to Axillary Lymph Node Negativity After Neoadjuvant Chemotherapy (NSABP B51/RTOG 1304 trial)	Dr. A Kesava Ramgopal
12:05 - 12:30	Panel Discussion Moderator: Dr. Sudha Sinha Panelists: Dr. Kishore Kumar Kota, Dr. Praveen NVS, Dr. Rajesh Kota, Dr. Vishwajeeth Pai, Dr. Nagender Sharma, Dr. A Kesava Ramgopal & Dr. Gundrathi Vamsivihari	
12:30 pm to 12:50 pm	<b>Sponsored Session 12 (AstraZeneca)</b> ADCs in HER2-ve & evolution of HER2 classification Speaker - Dr. Sainath Bhethanabhotla	
12:50 pm to 1:10 pm	<b>Sponsored Session 13 (MSD)</b> Redefining treatment outcomes with immunotherapy Early Triple Negative Breast Cancer Speaker - Dr. Rakesh Reddy Boya	
1:10 pm to 1:25 pm	<b>Conclusion &amp; Vote of Thanks</b>	
1:25 pm Onwards	<b>Lunch</b>	